CompletedNot Applicable

Laparoscopic Sleeve Gastrectomy-Induced Decline in Plasma Asprosin and Its Association With Metabolic Recovery

China85 participantsStarted 2021-01-01

Plain-language summary

the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age between 18 and 65 years;
✓. body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity;
✓. availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.

Exclusion criteria

✕. history of prior bariatric or gastrointestinal surgery;
✕. active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction;
✕. pregnancy during the study period;
✕. incomplete clinical or biochemical data.

What they're measuring

Plasma asprosin levels at 3, 6, and 12 months

Timeframe: 1 year

Trial details

NCT IDNCT07008274

SponsorNorthern Jiangsu People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-31

View on ClinicalTrials.gov More Obesity, Morbid trials